Therapeutic treatment for congestive heart failure

• US 4,762,820 A
• Filed: 03/03/1986
• Issued: 08/09/1988
• Est. Priority Date: 03/03/1986
• Status: Expired due to Fees

• Current Assignee: Trustees of Boston University
• Original Assignee: Trustees of Boston University
• Inventors: Gavras, Haralambos
• Primary Examiner(s): NOT, DEFINED
• Assistant Examiner(s): Moezie, F. T.
• Application Number:
  US06/835,487
• Time in Patent Office: 890 Days
• Field of Search: 514/10, 514/11, 514/807
• US Class Current: 514/10.9
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 7/16 Oxytocins; Vasopressins; Related peptides
• CPC Class Codes: Y10S 930/15 Oxytocin or vasopressin; related peptides

Abstract

A novel therapeutic method for treating human and animal subjects afflicted with congestive heart failure is provided by administering effective dosages of a selective antagonist for arginine vasopressin to the subject. The antagonist is an effective and potent inhibitor for vasopressin and is a therapeutic agent selected from the class consisting of analogues of previously prepared compositions synthesized in a conventionally known manner. The administration of such selective antagonist as a therapeutic agent results in a demonstrated beneficial change in approximately thirty percent of tested individuals.

Claims

1. A therapeutic method for treating a subject afflicted with congestive heart failure comprising the step of administering an effective amount of an antagonist selective for arginine-vasopressin to the subject.

2. The therapeutic method as recited in claim 1 wherein said selective antagonist is [1-(β

-mercapto-β

,β

-cyclopentamethylenepropionic acid), 2-(O-methyl)tyrosine]arginine vasopressin.

3. The therapeutic method as recited in claim 1 wherein said selective antagonist is selected from the group consisting of:

[1-(β

-mercapto-β

,β

cyclopentamethylenepropionic acid),2-(O-methyl)-D-tyrosine,4-valine,8-D-arginine]vasopressin;

[1-(β

-mercapto-β

,β

-cyclopentamethylenepropionic acid,2-(O-ethyl)-D-tyrosine,4-valine,8-D-arginine]vasopressin;

[1-(β

-mercapto-β

,β

-cyclopentamethylenepropionic acid),2-(O-isopropyl)-D-tyrosine,4-valine,8-D-arginine]vasopressin;

[1-(β

-mercapto-β

,β

-cyclopentamethylenepropionic acid),2-(O-n-propyl)-D-tyrosine,4-valine,8-D-arginine]vasopressin;

[1-(β

-mercapto-β

,β

-cyclopentamethylenepropionic acid),2-(O-methyl)-D-tyrosine,4-valine]arginine-vasopressin;

[1-(β

-mercapto-β

,β

-cyclopentamethylenepropionic acid),2-(O-ethyl)-D-tyrosine,4-valine]arginine-vasopressin;

[1-(β

-mercapto-β

,β

-cyclopentamethylenepropionic acid),2-(O-isopropyl)-D-tyrosine,4-valine]arginine-vasopressin;

[1-(β

-mercapto-β

,β

-cyclopentamethylenepropionic acid),2-(O-n-propyl)-D-Tyrosine,4-valine]arginine-vasopressin;

[1,(β

-mercapto-β

,β

-cyclopentamethylenepropionic acid),2-D-tyrosine,4-valine,8-D-arginine]vasopressin; and

[1-(β

-mercapto-β

,β

-cyclopentamethylenepropionic acid),2-D-tyrosine,4-valine]arginine-vasopressin.

4. The therapeutic method as recited in claim 1 wherein said administration is via the nasal mucosae.

5. The therapeutic method as recited in claim 1 wherein said administration is by intravenous injection.